KALA BIO Inc. - KALA Net earnings per one share for the last twelve months

The price trajectory of KALA BIO, Inc. (KALA) demonstrates a current metric of 78.30, driven by returns from the sale of patented anti-inflammatory drops. The business leverages its authority in ophthalmology through the use of stem cells for corneal regeneration. Currently, KALA BIO, Inc. (KALA) is executing a plan to complete key R&D research on rare pathologies to subsequently transfer innovation rights to corporate behemoths.
KALA (kalarx.com): analytical breakdowns and indicator data

Year-over-year EPS growth (TTM) reflects the dynamics of net income per share over a rolling year, determining market value through the discounting of future earnings. By analyzing the 12-month growth in earnings per share, investors assess capitalization momentum and the risks of an overbought asset. For KALA BIO, Inc. (KALA), this indicator confirms the effectiveness of monetizing stem cell therapy. The stability of this metric depends directly on the volume of insurance reimbursements for innovative ophthalmological drugs.